Drug Profile
Research programme: nitric oxide synthase type II inhibitors - Astellas Pharma
Alternative Names: FR-260330; Inducible nitric oxide synthase inhibitors - Astellas Pharma; iNOS inhibitors - Astellas PharmaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Small molecules
- Mechanism of Action Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Transplant-rejection in Japan
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma